Gå direkt till innehåll

Ämnen: Sjukdomar

Camallergy and OnDosis announce a groundbreaking partnership to revolutionize food allergy treatment

Camallergy and OnDosis announce a groundbreaking partnership to revolutionize food allergy treatment


Press release

Camallergy and OnDosis announce a groundbreaking partnership to revolutionize food allergy treatment
CAMBRIDGE, UK; GOTHENBURG, Sweden – 29 November 2023 – Camallergy, a pioneer in developing oral immunotherapy treatments for food allergies, and OnDosis, a leader in intelligent dosing of oral solid medicines, are excited to announce a strategic collaboration.
This

TIEFENBACHER GROUP and OnDosis launch the innovative healthcare brand OYSTA®

TIEFENBACHER GROUP and OnDosis launch the innovative healthcare brand OYSTA®

TIEFENBACHER GROUP and OnDosis are thrilled to announce the launch of OYSTA®. The new healthcare brand represents the cooperation initiated in September 2020, including the co-development portfolio of innovative products in five indications. OYSTA® aims to revolutionize the way how patients take their medicines by combining pharmaceuticals with e-health technology to enable intuitive, precise, and

OnDosis och Stardots ingår ett strategiskt samarbete för att kombinera banbrytande teknologier och möjliggöra bättre terapier för Parkinsons sjukdom

OnDosis och Stardots ingår ett strategiskt samarbete för att kombinera banbrytande teknologier och möjliggöra bättre terapier för Parkinsons sjukdom


OnDosis, ett svenskt medicinteknikbolag som utvecklar en unik device-plattform för flexibel och individanpassad dosering av läkemedel, och Stardots, ett svenskt digitalt hälsobolag som utvecklar produkter inom neurologi, meddelar idag att bolagen ingått ett strategiskt samarbete. Avsikten är att kombinera bolagens banbrytande teknologier för att möjliggöra utveckling av unika produkter för beh

Kallelse till årsstämma i OnDosis AB / Notice of annual general meeting 2022

Kallelse till årsstämma i OnDosis AB / Notice of annual general meeting 2022

Aktieägarna i OnDosis AB, org.nr 559113-1825 (”OnDosis” eller ”Bolaget”), kallas härmed till årsstämma tisdagen den 28 juni 2022 kl. 10.00 i Bolagets lokaler på AstraZeneca Bio VentureHub, Pepparedsleden 1 i Mölndal. Insläpp och registrering sker vid AstraZeneca KC entrén kl. 09:45.
The shareholders of OnDosis AB, reg. no. 556582-6558, (“OnDosis” or the “Company”) are hereby given notice of Ann

New agreement expands collaboration between OnDosis and Tiefenbacher Group, paving way for a revolution in how patients with rare disease take their medicines

New agreement expands collaboration between OnDosis and Tiefenbacher Group, paving way for a revolution in how patients with rare disease take their medicines


Swedish Life science company OnDosis and German B2B pharmaceutical company Tiefenbacher Group initiate four new innovative development projects targeting ADHD, rare diseases and transplantation medicine. The idea is to improve the health and everyday lives of millions of patients by giving them access to finely tuned and individualized medicine.
Tiefenbacher Group is a pioneering healthcar

New agreement expands collaboration between OnDosis and Tiefenbacher Group, opening a new chapter in precision medicine for rare disease and transplantation medicine

New agreement expands collaboration between OnDosis and Tiefenbacher Group, opening a new chapter in precision medicine for rare disease and transplantation medicine

Swedish Life science company OnDosis and German B2B pharmaceutical company Tiefenbacher Group initiate four new innovative development projects targeting ADHD, rare diseases and transplantation medicine. The idea is to improve the health and everyday lives of millions of patients by giving them access to finely tuned and individualized medicine

Visa mer

OnDosis – Changing the game, one dose at a time

Founded as a spin-out from AstraZeneca in 2017, OnDosis is a Swedish start-up addressing one of the major opportunities in healthcare; personalized dosage of medicines. The proprietary technology platform is centered around a connected handheld dosing device that delivers tailored doses of oral medicines. By combining individual dosing of traditional drug-based medicines augmented by digital therapeutics, OnDosis opens a new chapter in personalized medicine where the mission is to improve patients’ life through delivering the perfect dosage; individualized, intuitive, and intelligent.

OnDosis AB
Pepparedsleden 1
431 50 Mölndal
Sweden